[1]盛好,拉扎提?巴合提,徐杰,等.健脾祛湿方联合美沙拉嗪治疗克罗恩病疗效观察[J].西部中医药,2022,35(01):115-118.[doi:10.12174/j.issn.2096-9600.2022.01.28]
 SHENG Hao,LazhatiBAHETI,XU Jie,et al.Clinical Observation on Spleen-invigorating Dampness-eliminating Prescription and Mesalazine in Treating Crohn’s Disease[J].Western Journal of Traditional Chinese Medicine,2022,35(01):115-118.[doi:10.12174/j.issn.2096-9600.2022.01.28]
点击复制

健脾祛湿方联合美沙拉嗪治疗克罗恩病疗效观察
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年01期
页码:
115-118
栏目:
衷中参西
出版日期:
2022-01-15

文章信息/Info

Title:
Clinical Observation on Spleen-invigorating Dampness-eliminating Prescription and Mesalazine in Treating Crohn’s Disease
作者:
盛好 拉扎提?巴合提 徐杰 雷云霞
新疆医科大学附属中医医院,新疆 乌鲁木齐 830000
Author(s):
SHENG Hao Lazhati?BAHETI XU Jie LEI Yunxia
TCM Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, China
关键词:
克罗恩病健脾祛湿方美沙拉嗪临床疗效
Keywords:
CDspleen-invigorating dampness-eliminating prescriptionmesalazineclinical effects
分类号:
R574
DOI:
10.12174/j.issn.2096-9600.2022.01.28
摘要:
目的观察健脾祛湿方联合美沙拉嗪治疗克罗恩病(Crohn’s disease,CD)的效果。 方法将82例克罗恩病患者随机分为试验组和对照组各41例,对照组予美沙拉嗪干预,试验组在对照组干预基础上配合健脾祛湿方治疗,12周后比较两组患者CD活动指数(CDAI)评分和CD简化内镜(SES-CD)评分、分泌型磷脂酶A2(secretory phospholipase-A2,sPLA2)、红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reaction protein,CRP)、白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)和单核细胞趋化因子1(monocyte chemoattractant protein-1,MCP-1)的含量。 结果治疗后试验组CDAI和SES-CD评分较对照组低,差异具有统计学意义(P<0.01);试验组sPLA2、ESR、CRP低于对照组,差异具有统计学意义(P<0.05);与治疗前比较,两组患者IL-6、TNF-α和MCP-1水平均下降,差异具有统计学意义(P<0.01);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。 结论健脾祛湿方联合美沙拉嗪能更好地改善CD患者症状,改善炎症状态,且安全性良好。
Abstract:
ObjectiveTo survey clinical effects of spleen-invigorating dampness-eliminating prescription and mesalazine in the treatment of CD. MethodsAll 82 CD patients were randomized into the experiment group and the control group, 41 cases each group, the control group accepted the intervention of mesalazine, and the experiment group took spleen-invigorating dampness-eliminating prescription based on the intervention of the experiment group, to compare CDAI scores, SES-CD scores, sPLA2, ESR, CRP, IL-6, TNF-α and MCP-1 between both groups over 12 weeks. ResultsCDAI and SES-CD scores of the experiment group were lower than these of the control group after treating, and the difference had statistical meaning (P<0.01); the experiment group was lower than the control group in sPLA2, ESR and CRP, and the difference was statistically significant (P<0.05); Compared with before treating, the levels of IL-6, TNF-α and MCP-1 lowered in the two groups, and the difference had statistical meaning (P<0.01); the difference had no statistical meaning in the incidence of adverse reaction between both groups (P>0.05). ConclusionSpleen-invigorating dampness-eliminating prescription and mesalazine could improve the symptoms of the patients and inflammatory state with good safety.

备注/Memo

备注/Memo:
盛好(1984—),女,硕士学位,主治医师。研究方向:脾胃病的临床与基础研究。2018年新疆维吾尔自治区卫计委青年医学科技人才专项科研项目(2018Y47)。
更新日期/Last Update: 2022-01-15